ClinicalTrials.gg

Program

ORMD-0801

Also written as “ORMD-0801 8 mg”, “ORMD-0801 16 mg” and “ORMD-0801 (Insulin) capsule 8 mg BD”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1, led by Oramed.

Furthest: phase 3, since Feb 8, 20218 company-led studies, 1 open or runningNext primary completion: Apr 25, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Oramed81 open or runningphase 3since Feb 8, 2021Mar 20, 2014Apr 25, 2027phase 3 · NCT06731075

Also a collaborator on its studies: integrium.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 20, 2014First study: phase 2 study in Diabetes Mellitus, Type 1First studyNCT02094534 · 25 enrolled · United States
  2. Jul 8, 2015Phase 2 study in Diabetes Mellitus, Type 2NCT02496000 · 188 enrolled · United States
  3. Oct 13, 2016Phase 2 study in Diabetes Mellitus, Type 2NCT02954601 · 31 enrolled · United States
  4. Mar 1, 2018Phase 2 study in Diabetes Mellitus, Type 2NCT03467932 · 373 enrolled · United States
  5. Sep 21, 2020Phase 2 study in Diabetes Mellitus, Type 2NCT04564846 · 49 enrolled · United States
  6. Nov 1, 2020Phase 2 study in Diabetes Mellitus, Type 2NCT04618744 · 32 enrolled · United States, Israel
  7. Feb 8, 2021Phase 3 study in Diabetes Mellitus, Type 2NCT04754334 · 346 enrolled · United States
  8. Dec 9, 2024Phase 3 study in Diabetes Mellitus, Type 2NCT06731075 · 300 planned · United States

Ahead

  1. Apr 25, 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2NCT06731075

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06731075Diabetes Mellitus, Type 2 · United States3Not yet recruitingApr 25, 2027300
NCT04754334Diabetes Mellitus, Type 2 · United States3TerminatedJan 13, 2023346
NCT04618744Diabetes Mellitus, Type 2 · United States, Israel2CompletedJun 27, 202232
NCT04564846Diabetes Mellitus, Type 2 · United States2CompletedJun 7, 202249
NCT03467932Diabetes Mellitus, Type 2 · United States2CompletedOct 21, 2019373
NCT02954601Diabetes Mellitus, Type 2 · United States2CompletedFeb 24, 201731
NCT02496000Diabetes Mellitus, Type 2 · United States2CompletedJun 27, 2016188
NCT02094534Diabetes Mellitus, Type 1 · United States2CompletedAug 201425

How it is read

Names in the registry

  • “ORMD-0801”, 3 entries
  • “ORMD-0801 8 mg”, 1 entry
  • “ORMD-0801 16 mg”, 1 entry
  • “ORMD-0801 (Insulin) capsule 8 mg BD”, 1 entry
  • “Cohort A: ORMD-0801”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.